TY - JOUR
T1 - SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma
T2 - Phase 1 study
AU - Morgensztern, Daniel
AU - Johnson, Melissa
AU - Rudin, Charles M.
AU - Rossi, Michael
AU - Lazarov, Mirella
AU - Brickman, Daniel
AU - Fong, Abraham
N1 - Funding Information:
AbbVie and the authors thank the patients who participated in this clinical trial and all the study investigators, coordinators, and support staff for their contributions, including Bilal Tariq and Shekman Wong (pharmacokinetic analyses). Medical writing support was provided by Mary L. Smith, PhD, CMPP, Aptitude Health, Atlanta, GA, funded by AbbVie.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/7
Y1 - 2020/7
N2 - Objectives: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. Materials and methods: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. Results: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. Conclusion: SC-002 treatment was associated with systemic toxicity and limited efficacy.
AB - Objectives: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. Materials and methods: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. Results: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. Conclusion: SC-002 treatment was associated with systemic toxicity and limited efficacy.
KW - Antibody-drug conjugate
KW - Delta-like ligand 3
KW - Large cell neuroendocrine carcinoma
KW - Pyrrolobenzodiazepine
KW - SC-002
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85085144622&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2020.04.017
DO - 10.1016/j.lungcan.2020.04.017
M3 - Article
C2 - 32438272
AN - SCOPUS:85085144622
SN - 0169-5002
VL - 145
SP - 126
EP - 131
JO - Lung Cancer
JF - Lung Cancer
ER -